Effect of low dose Atomoxetine on stress/anxiety levels and cardiovascular risk in patients with hypertension, hypercholesterolemia, diabetes or other cardiovascular disease.
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Atomoxetine (Primary)
- Indications Anxiety
- Focus Therapeutic Use
- 21 Jun 2016 Status changed from recruiting to discontinued.
- 23 Jun 2015 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry record.
- 29 Apr 2015 New trial record